Physician profile
Hashim Mann
NPI 1912350026
$6,124.19
in general payments reported to CMS, 2019-2025
11 companies · $2,928 in 2025
The $2,928 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2023: $1,180 · 2024: $1,916 · 2025: $2,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,823 · Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,822.50 |
| Food and Beverage | $1,201.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,459.25 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Janssen Scientific Affairs, LLC | $2,227.50 | 2024-2025 | Tecvayli, Darzalex |
| Genzyme Corporation | $691.33 | 2023-2025 | |
| Beigene USA, INC. | $197.14 | 2023 | Brukinsa |
| Pfizer INC. | $152.96 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $108.84 | 2023 | Clonoseq |
| Johnson & Johnson Health Care Systems INC. | $106.68 | 2024 | Darzalex, Talvey, Tecvayli |
| Seagen INC. | $99.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $80.50 | 2023 | Pomalyst |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hashim Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.